In recent years, companies in the pharmaceutical industry have faced great pressure and have to find new ways
out.
Flush data statistics show that since 2022, more than 1,400 executives in the A-share biomedical industry have left, involving more than 350 companies
.
From the perspective of the subdivision track to which these enterprises belong, they are mainly concentrated in the fields
of chemical drugs, traditional Chinese medicine, and APIs.
In the field of chemical medicine, such as the "first brother of medicine" Hengrui, senior management changes frequently during the year, among which deputy general managers Zhang Yuehong, Zou Jianjun, Tao Weikang, etc.
have resigned
one after another.
The company's 2022 half-year report shows that the company's sales staff decreased by more than 2,300 during the reporting period, and the current sales team is less than 11,000
.
After layoffs, the company's sales expenses in the first half of the year were 3.
267 billion yuan, a year-on-year decrease of 29.
98%.
At the same time, Hengrui's senior management continued to introduce new talents, following the appointment of Dai Hongbin as general manager in May this year, Hengrui Pharmaceutical's senior management team was adjusted again in the third quarter of this year, and He Feng was newly appointed as the deputy general manager of Hengrui Pharmaceutical, which has been engaged in R&D in the pharmaceutical industry for more than 20 years and has both Hengrui Gene and global R&D background
.
Hengrui said that in the face of the external situation of industry changes and intensified competition, it will continue to promote the evolution of organizational operations, optimize corporate governance, and provide organizational mechanism guarantee
for the company's innovation and transformation and development.
The appointment of the new deputy general manager of R&D will help the company to further inject "new blood"
on the basis of ensuring the continuity and stability of innovative R&D.
In the field of traditional Chinese medicine, a large number of traditional Chinese medicine enterprises, including China Resources Sanjiu, Dong'a Jiao, Pian Zixi, Guangyuyuan, Yiling Pharmaceutical, etc.
, have changed their senior management during the year, including chairman, general manager, deputy general manager, vice president and other positions
.
For example, Guangyuan, which is actively transforming, had frequent executive changes in September
.
On September 23, Li Xiaojun, vice chairman of Guangyuyuan, resigned as a director, vice chairman and audit committee of the company's seventh board of directors, and President Zhang Bin resigned as president of the company due to work adjustment; Vice President Miao Hui resigned as
vice president due to work reasons.
On September 26, the company announced the appointment of Zhang Bin as the vice chairman of Guangyu Yuan Traditional Chinese Medicine Co.
, Ltd.
and Miao Hui as the president of
Guangyu Yuan Chinese Medicine Co.
, Ltd.
In July, the general managers of a number of pharmaceutical companies also announced their resignations, including Wang Hongxin of China Pharmaceutical, Feng Youshun of Zixin Pharmaceutical, and Zhang Wei of Renhe Pharmaceutical, all of whom resigned as general managers due to job
adjustments.
In addition, in the field of APIs, some senior executives of leading enterprises are also more frequent
.
As announced by Propharma on May 18, according to the company's business development needs, after the nomination of the company's general manager Xu Xinliang and the review of the nomination committee of the company's board of directors, the company's board of directors agreed to appoint He Chun as the company's senior deputy general manager, and he will no longer serve as the company's deputy general manager; At the same time, it was agreed to appoint Cai Lei as the company's deputy general manager
.
Cylon Pharmaceutical announced on November 2 that Mr.
Tong Yan applied to resign as the company's deputy general manager due to personal reasons, and after his resignation, he will not hold any position
in the company and its subsidiaries.
To a certain extent, the departure of some executives of traditional pharmaceutical companies may mean that the transformation of enterprises is facing problems such as insufficient growth momentum, but it may also be to meet the needs of enterprise transformation and adjustment, and it is expected that the next executive changes will continue
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
